SFDA Drafts New Fast Track Procedures For Drug Registration
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China regulators released a streamlined draft drug approval rule this month that would provide for faster approval of four categories of new drugs. The State Food and Drug Administration finished collecting public comments on the rule Oct. 15
You may also be interested in...
Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy
Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.
China Issues Fast-Track Registration For Drugs To Balance Innovation And Risk
Drugs and APIs in four categories now can gain approval in 120 days, down from 150.
China Issues Fast-Track Registration For Drugs To Balance Innovation And Risk
Drugs and APIs in four categories now can gain approval in 120 days, down from 150.